MET is a proto oncogene commonly seen in lung cancer patients.MET amplification is associated with poor prognosis in patients with non-small cell lung cancer.It is involved in the proliferation, survival, apoptosis, invasion, migration and angiogenesis of lung cancer cells.Studies have confirmed that MET amplification is related to the resistance of the first generation and the three generation of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Patients were treated with Crizotinib to overcome the effect of MET amplification on EGFR-TKI resistance.
Key words:
MET amplification; Epidermal growth factor receptor-tyrosine kinase inhibitor; Resistance; Carcinoma, non-small-cell lung